- Home
- BCDA vs ENSC Comparison
BCDA vs ENSC Comparison
Compare BCDA & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- ENSC
- Stock Information
- Founded
- BCDA N/A
- ENSC 2003
- Country
- BCDA United States
- ENSC United States
- Employees
- BCDA N/A
- ENSC N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- BCDA Health Care
- ENSC Health Care
- Exchange
- BCDA Nasdaq
- ENSC Nasdaq
- Market Cap
- BCDA 7.9M
- ENSC 9.5M
- IPO Year
- BCDA N/A
- ENSC N/A
- Fundamental
- Price
- BCDA $2.05
- ENSC $6.07
- Analyst Decision
- BCDA Strong Buy
- ENSC
- Analyst Count
- BCDA 1
- ENSC 0
- Target Price
- BCDA $25.00
- ENSC N/A
- AVG Volume (30 Days)
- BCDA 31.3K
- ENSC 154.9K
- Earning Date
- BCDA 11-13-2024
- ENSC 11-12-2024
- Dividend Yield
- BCDA N/A
- ENSC N/A
- EPS Growth
- BCDA N/A
- ENSC N/A
- EPS
- BCDA N/A
- ENSC N/A
- Revenue
- BCDA $71,000.00
- ENSC $4,421,404.00
- Revenue This Year
- BCDA N/A
- ENSC N/A
- Revenue Next Year
- BCDA N/A
- ENSC N/A
- P/E Ratio
- BCDA N/A
- ENSC N/A
- Revenue Growth
- BCDA N/A
- ENSC 40.41
- 52 Week Low
- BCDA $1.84
- ENSC $2.12
- 52 Week High
- BCDA $10.80
- ENSC $30.90
- Technical
- Relative Strength Index (RSI)
- BCDA 42.16
- ENSC 42.77
- Support Level
- BCDA $2.00
- ENSC $5.34
- Resistance Level
- BCDA $2.14
- ENSC $8.27
- Average True Range (ATR)
- BCDA 0.16
- ENSC 1.06
- MACD
- BCDA -0.00
- ENSC -0.24
- Stochastic Oscillator
- BCDA 15.91
- ENSC 18.43
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.